iBio, Inc.
$1.43 +$0.03 (+2.14%) 1D After hours
iBio, Inc.
Key Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 17
A material event was filed (Form 8-K).
8-K - iBio, Inc. (0001420720) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
From its Feb 26 high, the share price fell 56%.
Peak close $3.07 on Feb 26; trough close $1.35 on Jul 16. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -56% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Mar 26
The stock moved -20.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 26 -
Feb 25
The stock moved +16.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 25
The story updates itself as events post · The wolf reports; you decide
Snapshot
About iBio, Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.